Share on StockTwits

Amphastar Pharmaceuticals’ (NASDAQ:AMPH) quiet period will end on Monday, August 4th. Amphastar Pharmaceuticals had issued 8,000,000 shares in its initial public offering on June 25th, StockRatingsNetwork reports. The total size of the offering was $56,000,000 based on an initial share price of $7.00. During the company’s quiet period, underwriters and any insiders that worked on the IPO are prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

A number of research firms have recently commented on AMPH. Analysts at Needham & Company LLC initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Monday, July 21st. They set a “buy” rating and a $17.00 price target on the stock. Separately, analysts at Piper Jaffray initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Monday, July 21st. They set an “overweight” rating and a $16.00 price target on the stock. Finally, analysts at BMO Capital Markets initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Monday, July 21st. They set an “outperform” rating and a $17.00 price target on the stock.

Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) traded down 0.45% on Friday, hitting $8.84. 38,302 shares of the company’s stock traded hands. Amphastar Pharmaceuticals has a 1-year low of $6.67 and a 1-year high of $11.07. The stock has a 50-day moving average of $9.31 and a 200-day moving average of $9.31. The company has a market cap of $383.7 million and a price-to-earnings ratio of 43.74.

Amphastar Pharmaceuticals, Inc is a specialty and generic pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling technically challenging generic and injectable and inhalation products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.